BNTX

The Centers for Disease Control and Prevention recommended use of Moderna Inc.’s Covid-19 vaccine in children ages 6 to 17 years.The CDC’s move on Friday means the youths, who have been able to get the Covid-19 vaccine made by Pfizer Inc. and its partner BioNTech SE, will also have the choice of Moderna’s shot. The Centers for Disease Control and Prevention recommended use of ModernaInc.’s Covid-19 vaccine in children ages 6 to 17 years.The CDC’s move on Friday means the youths, who have been able to get the Covid-19…

Advisers to the Centers for Disease Control and Prevention are set to decide whether to recommend Moderna Inc.’s Covid-19 vaccine for children ages 6 to 17 years. Children in the age group already have access to Covid-19 vaccines made by Pfizer Inc. and its partner BioNTech SE. The advisers are scheduled to discuss on Thursday whether Moderna’s shot should also be made available for that age range.…

Some 1½ years after first authorizing the shots for people of older ages, the Food and Drug Administration on Friday expanded use of the vaccines to the nearly 20 million children in the U.S. from 6 months to under 5 years. A national campaign to vaccinate the young children is expected to kick off as soon as Monday, after the Centers for Disease Control and Prevention signs off in the coming days. To be ready, the Biden administration has been gearing up to get sufficient supplies of the shots to hospitals,…

A positive recommendation would likely lead soon to expanding the U.S. Covid-19 vaccination campaign to the 19.6 million children 6 months old to under 5 years of age, the last group of people in the U.S. waiting for shots. Moderna’s two-dose vaccine is up for the Food and Drug Administration’s authorization in children 6 months to 5 years, while Pfizer’s three-dose shot is under review for children 6 months to 4 years. FDA staff have reviewed data from the companies’ clinical trials, finding the vaccines were…

A panel of advisers to the Food and Drug Administration is set to meet Tuesday to consider whether use of Moderna Inc.’s Covid-19 vaccine should be expanded to include children ages 6 through 17.The advisory committee is expected to vote Tuesday afternoon on whether the benefits of vaccinating children in this age group outweigh the risks. The FDA will consider the vote in making a final decision on whether to clear the vaccine for use in children 6 years and older. An FDA authorization could…

A Covid-19 vaccine developed by Sanofi SA and GSK PLC to target the Beta strain of the virus produced a stronger antibody response against variants of Omicron when given as a booster compared with certain first-generation shots, two studies have found.The results are the latest indication that tweaking vaccines can nudge antibody responses in the direction of new variants, possibly helping to shore up immunity as the virus mutates. The study results may also provide an opportunity for Sanofi…

The FDA staff also said, in a review of study data posted online Sunday, that there were no new safety concerns using the vaccine in young children compared with older age groups. The assessment is the latest sign that authorities are moving closer to clearing inoculations for children under 5 years old, the last group ineligible for Covid-19 vaccination. On Friday, the FDA released a staff review finding that two doses of Moderna Inc.’s Covid-19 vaccine were generally safe and effective in children ages 6…

Moderna Inc.’s Covid-19 vaccine was effective at preventing symptomatic disease in children ages 6 months through 5 years, Food and Drug Administration staff said in a review of the evidence.The FDA staff also said Friday that Moderna’s vaccine was generally safe in children in studies, including those under 5 years who haven’t had access to any shots. The assessment of the vaccine, part of the FDA’s standard process for deciding whether to permit use of a medicine, might bode well for the…

The outside panel of experts will vote on whether the shot should be authorized, after the agency found it effective but flagged a safety concern. The outside panel of experts will vote on whether the shot should be authorized, after the agency found it effective but flagged a safety concern. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All…

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/pfizer-asks-fda-to-authorize-its-covid-19-vaccine-for-children-under-5-11654120180 This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our…